TY  - JOUR
AU  - Dafsari, Haidar S.
AU  - Martinez‐Martin, Pablo
AU  - Rizos, Alexandra
AU  - Trost, Maja
AU  - Santos Ghilardi, Maria Gabriela
AU  - Reddy, Prashanth
AU  - Sauerbier, Anna
AU  - Petry‐Schmelzer, Jan Niklas
AU  - Kramberger, Milica
AU  - Borgemeester, Robbert W. K.
AU  - Barbe, Michael T.
AU  - Ashkan, Keyoumars
AU  - Silverdale, Monty
AU  - Evans, Julian
AU  - Odin, Per
AU  - Fonoff, Erich Talamoni
AU  - Fink, Gereon R.
AU  - Henriksen, Tove
AU  - Ebersbach, Georg
AU  - Pirtošek, Zvezdan
AU  - Visser‐Vandewalle, Veerle
AU  - Antonini, Angelo
AU  - Timmermann, Lars
AU  - Ray Chaudhuri, K.
TI  - EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
JO  - Movement disorders
VL  - 34
IS  - 3
SN  - 1531-8257
CY  - New York, NY
PB  - Wiley
M1  - FZJ-2019-01372
SP  - 353-365
PY  - 2019
AB  - ObjectiveReal‐life observational report of clinical efficacy of bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD).MethodsIn this prospective, multicenter, international, real‐life cohort observation study of 173 PD patients undergoing STN‐DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed‐up using PDQuestionnaire‐8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)‐III, UPDRS‐IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed‐rank or paired t test when parametric tests were applicable. Multiple comparisons were corrected (multiple treatments/scales). Effect strengths were quantified with relative changes, effect size, and number needed to treat. Analyses were computed before and after propensity score matching, balancing demographic and clinical characteristics.ResultsIn all groups, PDQuestionnaire‐8, UPDRS‐IV, and NMSS total scores improved significantly at follow‐up. Levodopa equivalent daily dose was significantly reduced after STN‐DBS. Explorative NMSS domain analyses resulted in distinct profiles: STN‐DBS improved urinary/sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the 3 latter domains and gastrointestinal symptoms. APO improved mood/cognition, perceptual problems/hallucinations, attention/memory, and the miscellaneous domain. Overall, STN‐DBS and IJLI seemed favorable for NMSS total score, and APO favorable for neuropsychological/neuropsychiatric NMS and PDQuestionnaire‐8 outcome.ConclusionsThis is the first comparison of quality of life, nonmotor. and motor outcomes in PD patients undergoing STN‐DBS, IJLI, and APO in a real‐life cohort. Distinct effect profiles were identified for each treatment option. Our results highlight the importance of holistic nonmotor and motor symptoms assessments to personalize treatment choices. © 2019 International Parkinson and Movement Disorder Society
LB  - PUB:(DE-HGF)16
C6  - pmid:30719763
UR  - <Go to ISI:>//WOS:000461871300009
DO  - DOI:10.1002/mds.27626
UR  - https://juser.fz-juelich.de/record/860707
ER  -